Skip to main content

Table 3 Adverse events and laboratory abnormalities during the treatment period

From: Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis

  Chronic hepatitis (n = 14) (%) Compensated cirrhosis (n = 4) (%)
  < Grade 3 ≥ Grade 3 < Grade 3 ≥ Grade 3
Pruritus 4 (28.6) 0 3 (75.0) 0
Headache 1 (7.1) 0 0 0
Bloating 0 0 1 (25.0) 0
Fatigue 0 0 1 (25.0) 0
Cellulitis 0 0 0 1 (25.0)